<DOC>
	<DOCNO>NCT03023020</DOCNO>
	<brief_summary>The study compare two lengths medication therapy ( shorten versus prolong dual antiplatelet therapy ) order prevent thrombus ( blood cloth ) formation successfully treatment coronary heart disease drug cover stent ( metallic tube ) . This comparison do patient , compare average patient , likely suffer complication antiplatelet therapy ( bleed ) . Both duration within current medical recommendation . The aim study help improve standard antiplatelet duration guideline .</brief_summary>
	<brief_title>Management High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With Abbreviated Versus Prolonged DAPT Regimen</brief_title>
	<detailed_description>The study objective determine high bleeding risk patient population undergo PCI standardized treatment ( within current guideline instruction use include bioresorbable polymer coat Ultimaster sirolimus-eluting stent ) , whether abbreviate DAPT non-inferior prolong DAPT regimen term NACE within 12 month , whether abbreviate DAPT non-inferior prolong DAPT regimen term MACCE within 12 month whether abbreviated DAPT superior prolong DAPT regimen term MCB within 12 month . There two treatment strategy : - abbreviate dual anti-platelet therapy : dual antiplatelet therapy discontinue single antiplatelet agent continue least 11 month post randomization ( i.e . 12 month post stent implantation ) . In patient oral anticoagulant , dual antiplatelet therapy discontinue either Aspirin Clopidogrel continue 5 month post randomization ( i.e . 6 month post stent implantation ) . Oral anticoagulation continue least 11 month post randomization ( i.e . 12 month post stent implantation ) OR - prolonged dual anti-platelet therapy : aspirin continue least 11 month post randomization ( i.e . 12 month post stent implantation ) , P2Y12 inhibitor take time randomization continue least 5 month 11 month post randomization ( i.e . 12 month post stent implantation ) . In patient oral anticoagulant , aspirin Clopidogrel continue least 2 month post randomization ( i.e . 3 month post stent implantation ) 11 month post randomization ( i.e . 12 month stent implantation ) . Therefore either aspirin Clopidogrel continue 11 month post randomization ( i.e . 12 month post stent implantation ) The study design investigator-initiated , randomize , multi-center , clinical trial conduct approximately 100 interventional cardiology center across globe exclude USA . The study include 2 x 2150 patient ( i.e . 4300 patient ) Randomization occur one month PCI procedure . The expected duration participation patient 14 month .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>After index PCI , patient age 18 year eligible inclusion study follow criterion meet . 1 . At least one among HBR criterion ( define ) meet . 2 . All lesion successfully treat Ultimaster stent context routine clinical care , i.e . postprocedural angiographic diameter stenosis &lt; 20 % visual estimation 3 . Free flowlimiting angiographic complication ( i.e . significant untreated dissection major sidebranch occlusion ) , require prolonged DAPT duration base operator 's opinion . 4 . All stage PCI complete ( ) PCI plan . At randomization visit ( one month index PCI ) , follow criterion must meet : 1 . Fulfilment least one HBR criterion ( define ) , basis postPCI actionable ( i.e . require medical attention ) nonaccess site relate bleed episode 2 . Uneventful 30day clinical course , i.e . free spontaneous MI , symptomatic restenosis , stent thrombosis , stroke revascularization ( coronary noncoronary ) require prolong DAPT 3 . If OAC , 1 . Patient DAPT regimen aspirin P2Y12 inhibitor 2 . Patient one type P2Y12 inhibitor least 7 day ( i.e . switch oral P2Y12 inhibitor occur previous 7 day ) 4 . If OAC 1 . Patient type OAC ( e.g . Vitamin K antagonist NOAC ) least 7 day 2 . Patient clopidogrel least 7 day Definition HBR PostPCI patient HBR least one follow criterion applies : Clinical indication treatment oral anticoagulant ( OAC ) least 12 month Recent ( &lt; 12 month ) nonaccess site bleeding episode ( ) , require medical attention ( i.e . actionable bleeding ) . Previous bleed episode ( ) require hospitalization underlie cause definitively treat ( i.e . surgical removal bleed source ) Age equal great 75 year Systemic condition associate increase bleed risk ( e.g . haematological disorder , include history current thrombocytopaenia define platelet count &lt; 100,000/mm3 ( &lt; 100 x 109/L ) , know coagulation disorder associate increase bleed risk . Documented anaemia define repeat haemoglobin level &lt; 11 g/dl transfusion within 4 week randomization . Need chronic treatment steroid nonsteroidal antiinflammatory drug Diagnosed malignancy ( skin ) consider high bleeding risk include gastrointestinal , genitourethral/renal pulmonary . Stroke time TIA previous 6 month PRECISE DAPT score 25 great 1 . Treated stent Ultimaster stent within 6 month prior index procedure 2 . Treated instent restenosis stent thrombosis index PCI within 6 month 3 . Treated bioresorbable scaffold time prior index procedure 4 . Can provide write informed consent 5 . Under judicial protection , tutorship curatorship 6 . Unable understand follow studyrelated instruction unable comply study protocol 7 . Active bleed require medical attention ( BARCâ‰¥2 ) randomization visit 8 . Life expectancy less one year 9 . Known hypersensitivity allergy aspirin , clopidogrel , ticagrelor , prasugrel , cobalt chromium sirolimus 10 . Any planned anticipate PCI 11 . Participation another trial 12 . Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Dual Antiplatelet Therapy</keyword>
</DOC>